

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

INSIDE INFORMATION TAX-RELATED ISSUE INVOLVING A SUBSIDIARY

This announcement is made by China Isotope & Radiation Corporation (the “**Company**”) pursuant to Rule 13.09(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that on 31 December 2025, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd. (“**Headway**”), a non-wholly-owned subsidiary of the Company, as determined by the relevant competent authorities, is required to pay additional corporate income tax, value-added tax and other taxes of RMB188 million for the period from 1 January 2021 to 31 December 2024, plus late payment surcharges, resulting in a total amount of RMB271 million in a short time, which primarily focused on items such as Headway’s sales expenses and abnormal inventory losses during the aforementioned period. No administrative penalties were imposed in this case.

As at the date of this announcement, Headway has completed the payment of the aforementioned taxes. It is expected that the tax-related issue will impact the profit for the year attributable to equity Shareholders in 2025 by approximately RMB130 million. However, the actual financial impact associated with the settlement will be subject to the review and audit results of the independent auditor of the Company.

The Company attaches great importance to the aforementioned matter and will further enhance its own management capabilities to effectively safeguard the interests of the Company and its Shareholders.

The Company will make further announcement(s) to keep Shareholders and potential investors informed of any further developments as and when appropriate.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
China Isotope & Radiation Corporation
Xiao Yafei
Chairman

Beijing, the PRC, 31 December 2025

As at the date of this announcement, the Board comprises Mr. Xiao Yafei, Mr. Zhang Junqi, Ms. Huo Yingying and Ms. Ma Xiaoyu as executive Directors; Mr. Chen Zan, Mr. Ding Jianmin and Ms. Chang Jinyu as non-executive Directors; and Mr. Poon Chiu Kwok, Ms. Chen Jingshan, Mr. Lu Chuang and Mr. An Rui as independent non-executive Directors.